← Back to Clinical Trials
RecruitingNCT06230861

Effects of Quercetin on Cardiometabolic Outcomes

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionCardiometabolic Syndrome
SponsorUniversity of Central Lancashire
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment40
SexALL
Min Age18 Years
Max Age65 Years
Start Date2024-03-01
Completion2026-08-01
Interventions
QuercetinPlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

Eligibility Criteria

Inclusion Criteria: * Healthy * Between 18 \& 65 years * Non-smoker * BMI \< 30 * Able to give informed consent Exclusion Criteria: * Pregnancy * Diabetes or any other metabolic/ uncontrolled hypertensive conditions * Food allergies to quercetin * Habitual consumption of quercetin * Not regularly taking medication or antioxidant supplements

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology